uniQure

uniQure is a Dutch biopharmaceutical company focused on the discovery, development, manufacture, and commercialization of gene therapies. Its work is centered largely on adeno-associated virus, or AAV, delivery systems intended to introduce therapeutic genetic material into patients with inherited or otherwise serious diseases. The company has operated at the intersection of biotechnology research, clinical development, viral-vector manufacturing, and specialty pharmaceutical commercialization. The business traces its origins to 1998, when it was established as Amsterdam Molecular Therapeutics. It later adopted the uniQure name as the company developed a broader international identity in gene therapy. A major early milestone came in 2012, when the European Union authorized alipogene tiparvovec, marketed as Glybera, for lipoprotein lipase deficiency. Glybera became the first gene therapy to receive regulatory approval in the Western world. The product was designed for an exceptionally rare inherited metabolic disorder and used an AAV vector to deliver a functional copy of the relevant gene. Despite its historic significance, commercial demand remained very limited. The therapy was associated with a treatment price of more than US$1 million, and it was withdrawn from the market in 2017. Glybera demonstrated both the potential and the commercial difficulty of early gene-therapy products. The therapy required treatment of a very small patient population, involved a complex manufacturing and reimbursement model, and faced uncertainty concerning long-term adoption. Its withdrawal did not end uniQure's development strategy; instead, the company continued concentrating on diseases in which a one-time genetic intervention could provide a meaningful and durable clinical benefit. The company's most significant later commercial achievement was etranacogene dezaparvovec, marketed as Hemgenix. Developed for adults with hemophilia B, Hemgenix uses an AAV-based approach to deliver a gene encoding factor IX, the clotting protein deficient in people with hemophilia B. The United States Food and Drug Administration approved Hemgenix in 2022. uniQure partnered with CSL Behring for commercialization, allowing uniQure to combine its gene-therapy development and manufacturing capabilities with CSL Behring's presence in the hemophilia and specialty-care markets. Hemgenix was among the earliest approved gene therapies for a rare genetic disease and reinforced uniQure's position as a specialist in one-time or potentially durable treatments. uniQure has also pursued investigational programs in neurological disease, including AMT-130 for Huntington's disease. The program reflects the company's expansion beyond blood and metabolic disorders into diseases affecting the central nervous system, where direct administration and long-term safety are major development considerations. Regulatory interactions concerning AMT-130 included a change in the U.S. Food and Drug Administration's position on breakthrough-therapy designation, as described in the supplied reference material. Today, uniQure's identity is built around gene-therapy platforms, clinical programs for serious diseases, and the specialized manufacturing needed to produce viral-vector medicines. Its history includes a landmark first approval, the withdrawal of an early commercial product, and a later partnership-led launch of a major hemophilia treatment. The company remains active, with its prospects dependent on clinical data, regulatory decisions, manufacturing execution, reimbursement, and the ability to establish sustainable markets for high-cost genetic medicines.

uniQure originated in 1998 under the name Amsterdam Molecular Therapeutics. The company was established to develop genetic medicines and subsequently became associated with adeno-associated virus, or AAV, gene-therapy technology. It later adopted the uniQure name as it developed an international biopharmaceutical identity and pursued programs across inherited metabolic, hematological, and neurological diseases. Its first major regulatory achievement was alipogene tiparvovec, marketed as Glybera. In 2012, the therapy received approval for lipoprotein lipase deficiency, an exceptionally rare inherited metabolic disorder. The authorization was historically important because Glybera was the first gene therapy approved in the Western world. Its treatment approach used an AAV vector to deliver genetic material intended to restore production of lipoprotein lipase. The approval demonstrated that a one-time genetic intervention could reach the market, but it also exposed the difficulties of commercializing medicines for very small patient populations. Glybera's market experience was challenging. Demand was limited, in part because the eligible population was very small and the treatment cost exceeded US$1 million. Questions surrounding access, reimbursement, manufacturing, and the durability of the clinical benefit made adoption difficult. The product was removed from the market in 2017. This outcome became an important example of the gap that can exist between regulatory innovation and sustainable commercial use in gene therapy. uniQure continued developing AAV-based medicines after Glybera. Its most important later program was etranacogene dezaparvovec, marketed as Hemgenix, for hemophilia B. The treatment is designed to deliver a gene encoding factor IX, the clotting factor deficient in people with hemophilia B. In 2022, the U.S. Food and Drug Administration approved Hemgenix. uniQure partnered with CSL Behring to commercialize the product, combining uniQure's gene-therapy expertise with CSL Behring's established capabilities in hemophilia and specialty pharmaceuticals. Hemgenix became one of the earliest approved gene therapies for a rare genetic disease and gave uniQure a commercially significant product through a partnership model. The company also expanded into central nervous system disease. AMT-130 was developed as an investigational gene therapy for Huntington's disease, a progressive inherited neurological disorder. This program illustrates a strategic shift toward disorders where a genetic intervention may need to be administered directly to the brain and followed over an extended period for safety and efficacy. It also brought uniQure into complex regulatory discussions. The supplied reference material reports that the FDA changed its position regarding breakthrough-therapy designation for AMT-130 in late 2025 and later reversed that decision in June 2026. Those future-dated details require verification against authoritative regulatory and company records. Across its history, uniQure has therefore passed through several distinct phases: early platform and company formation; the landmark but commercially difficult Glybera launch; continued clinical and manufacturing development; and the partnership-supported commercialization of Hemgenix. Its business remains dependent on the technical challenges of AAV delivery, the ability to manufacture consistent vectors at scale, long-term clinical evidence, regulatory approval, pricing and reimbursement, and the creation of treatment pathways for rare-disease patients. The company's record is notable both for pioneering a first approved Western gene therapy and for participating in the later generation of gene therapies aimed at more established specialty-care markets.

• 2022

  Hemgenix approved in the United States

  [1]UniQureen.wikipedia.org

  The FDA approved etranacogene dezaparvovec, marketed as Hemgenix, for adults with hemophilia B. CSL Behring became uniQure's commercialization partner.

• 2017

  Glybera withdrawn from the market

  [1]UniQureen.wikipedia.org

  Glybera was taken off the market following limited demand, with its very high treatment cost and small eligible population cited as important factors.

• 2012

  Glybera receives approval

  [1]UniQureen.wikipedia.org

  Alipogene tiparvovec, marketed as Glybera, was approved for lipoprotein lipase deficiency and became the first gene therapy approved in the Western world.

• 1998

  Company established as Amsterdam Molecular Therapeutics

  [1]UniQureen.wikipedia.org

  The company that later became uniQure was established under the name Amsterdam Molecular Therapeutics.

A specialist gene-therapy developer focused on potentially durable treatments for rare and serious genetic diseases, with particular expertise in AAV-based medicines.

• Approved gene therapy · 2012

  Glybera

  Glybera was the trade name for alipogene tiparvovec, an AAV-based gene therapy for lipoprotein lipase deficiency. Its 2012 approval was a landmark for the field because it was the first gene therapy approved in the Western world. The product targeted an exceptionally rare inherited metabolic disease, but commercial uptake was limited. It was withdrawn from the market in 2017 after demand failed to support continued availability.

• Approved gene therapy · 2022

  Hemgenix

  Hemgenix is the trade name for etranacogene dezaparvovec, an AAV-based gene therapy for hemophilia B. The therapy delivers genetic material intended to enable production of factor IX, the clotting protein deficient in the disease. The FDA approved it in 2022. uniQure developed the therapy and partnered with CSL Behring for commercialization, making Hemgenix the company's most important approved product in its later history.

• Investigational gene therapy

  AMT-130

  AMT-130 is an investigational gene-therapy program for Huntington's disease. It represents uniQure's effort to apply its AAV expertise to a progressive neurological disorder and involves the additional challenges of delivery to the central nervous system, long-term monitoring, and assessment of clinical progression. The supplied reference material also describes changing FDA decisions concerning the program's breakthrough-therapy designation.

• 2022

  Launch Hemgenix through a CSL Behring partnershipProduct launch

  Background

  Hemgenix received FDA approval as a gene therapy for hemophilia B, creating an opportunity to commercialize a later-generation product in an established specialty-care market.

  Action taken

  uniQure partnered with CSL Behring to commercialize Hemgenix.

  Aftermath

  The partnership gave Hemgenix access to CSL Behring's hemophilia commercial infrastructure while allowing uniQure to focus on gene-therapy development and manufacturing expertise.

  Source

• 2017

  Withdraw Glybera from the marketOther

  Background

  Glybera had achieved historic regulatory status but attracted limited demand because it addressed an extremely rare disease and carried a treatment cost above US$1 million.

  Action taken

  uniQure discontinued the product and removed it from the market.

  Aftermath

  The withdrawal highlighted the commercial and reimbursement difficulties facing early gene therapies, despite their scientific and regulatory importance.

  Source

1. 1UniQureen.wikipedia.org